Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 10, 2013, Pages 1252-1261

  Langley, R G ^a   Papp, K ^b   Gottlieb, A B ^c   Krueger, G G ^d   Gordon, K B ^e   Williams, D ^f   Valdes, J ^f   Setze, C ^f   Strober, B ^g  

^a DALHOUSIE UNIVERSITY   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c TUFTS MEDICAL CENTER   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

^f ABBOTT LABORATORIES   (United States)

^g UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRIAKINUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL;

AFRICAN AMERICAN; AGE; AMERICAN INDIAN; ANGINA PECTORIS; ARTHRALGIA; ARTICLE; ASIAN; BACKACHE; BASAL CELL CARCINOMA; BODY MASS; BODY SURFACE; BODY WEIGHT; CANDIDIASIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELLULITIS; CHOLESTEROL BLOOD LEVEL; COCCIDIOIDOMYCOSIS; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE DURATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EAR INFECTION; EUROPEAN AMERICAN; FAINTNESS; GENDER; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LUNG EMBOLISM; LYMPHOMA; MEDICAL HISTORY; OPEN STUDY; OPPORTUNISTIC INFECTION; PACIFIC ISLANDER; PERIPHERAL VASCULAR DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PREDICTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RACE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RHINOPHARYNGITIS; SEPSIS; SINGLE DRUG DOSE; SINUSITIS; SMOKING; SQUAMOUS CELL CARCINOMA; SYSTOLIC BLOOD PRESSURE; THRUSH; TREATMENT WITHDRAWAL; UPPER RESPIRATORY TRACT INFECTION; VALVULAR HEART DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; INTERLEUKIN-12; INTERLEUKIN-23; MALE; MIDDLE AGED; PREVALENCE; PSORIASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SKIN DISEASES, INFECTIOUS; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84884900971     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04705.x     Document Type: Article

References (34)

1. Pathirana D, Ormerod AD, Saiag P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23: 1-70.
2. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
3. Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008; 22: 1337-1342.
4. Patel V, Horn EJ, Lobosco SJ, et al. Psoriasis treatment patterns: results of a cross-sectional survey of dermatologists. J Am Acad Dermatol 2008; 58: 964-969.
5. Augustin M, Kruger K, Radtke MA, et al. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-372.
6. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
7. Kimball AB, Gordon KB, Langley RG, et al. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008; 144: 200-207.
8. Gordon KB, Langley RG, Gottlieb AB, et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 2012; 132: 304-314.
9. Gottlieb AB, Leonardi C, Kerdel F, et al. Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 652-660.
10. Strober BE, Crowley JJ, Yamauchi PS, et al. Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. Br J Dermatol 2011; 165: 661-668.
11. Reich K, Langley RG, Papp KA, et al. A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis. N Engl J Med 2011; 365: 1586-1596.
12. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
13. D'Agostino RB, Russell MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 2000; 139: 272-281.
14. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
15. Gordon KB, Gottlieb AB, Leonardi CL, et al. Clinical response in psoriasis patients discontinued from and then reinitiated on etanercept therapy. J Dermatolog Treat 2006; 17: 9-17.
16. Papp KA, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 2005; 152: 1304-1312.
17. Kimball AB, Gordon KB, Fakharzadeh S, et al. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012; 166: 861-872.
18. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007. [WWW document] 2010. National Cancer Institute: Bethesda, MD URL http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010. (last accessed: 16 October 2012).
19. Boyle P, Levin B, (eds). World Cancer Report 2008. Lyon, France: World Health Organization. International Agency for Research on Cancer; 2008.
20. Langley RG, Gordon K, Olds M, Williams DA,. A pooled analysis of phase III, randomized, Placebo-Controlled clinical trials of the Anti-Interleukin 12/23 Monoclonal antibody, Briakinumab. J Am Acad Dermatol 2011; 64: AB8.
21. Strober BE, Gottlieb AB, Olds M, Williams DA,. Pooled safety and efficacy results from two phase III trials comparing Briakinumab with Etanercept and Placebo for the treatment of moderate to severe psoriasis. J Am Acad Dermatol 2011; 64: AB146.
22. Gordon K, Leonardi C, Griffiths CEM, et al. Ustekinumab safety update: cumulative experience from longer term follow-up of patients treated in the ustekinumab psoriasis clinical development program. Poster presented At: Summer Academy Meeting, American Academy of Dermatology. Chicago, Il, 2010: P2322.
23. Milner JD, Brenchley JM, Laurence A, et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature 2008; 452: 773-776.
24. Kagami S, Rizzo HL, Kurtz SE, et al. IL-23 and IL-17A, but not IL-12 and IL-22, are required for optimal skin host defense against Candida albicans. J Immunol 2010; 185: 5453-5462.
25. Puel A, Cypowyj S, Bustamante J, et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science 2011; 332: 65-68.
26. Boukamp P,. Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26: 1657-1667.
27. Maeda A, Schneider SW, Kojima M, et al. Enhanced photocarcinogenesis in interleukin-12-deficient mice. Cancer Res 2006; 66: 2962-2969.
28. Schwarz A, Stander S, Berneburg M, et al. Interleukin-12 suppresses ultraviolet radiation-induced apoptosis by inducing DNA repair. Nat Cell Biol 2002; 4: 26-31.
29. Reddy M, Torres G, McCormick T, et al. Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters. J Dermatol 2010; 37: 413-425.
30. Food and drug administration dermatologic and ophthalmic drugs advisory Committee. Briefing document for Ustekinumab (CNTO 1275). [WWW document] 2008. URL http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4361b1-02-CENTOCOR.pdf (last accessed: 25 July 2012).
31. Leonardi C, Papp K, Strober B, et al. The long-term safety of adalimumab treatment in moderate to severe psoriasis: a comprehensive analysis of all adalimumab exposure in all clinical trials. Am J Clin Dermatol 2011; 12: 321-337.
32. Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA 2011; 306: 864-871.
33. Tzellos T, Kyrgidis A, Zouboulis CC,. Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials. J Eur Acad Dermatol Venereol 2012; doi: 10.1111/j.1468-3083.2012.04500. x.[Epub ahead of print].
34. Reich K, Langley RG, Lebwohl M, et al. Cardiovascular safety of ustekinumab in patients with moderate to severe psoriasis: results of integrated analyses of data from phase II and III clinical studies. Br J Dermatol 2011; 164: 862-872.